Floatz logo

68ganota-anti-mmr-vhh2

Solid Malignancy Located in the Head and Neck

Universitair Ziekenhuis BrusselradiopharmaceuticalPhase 2Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

142 Active assets in the Solid Malignancy Located in the Head and Neck cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
FILGRASTIM
University of Colorado, Denver
Phase 2BB

View all 50 →

Same molecule, other indications

68ganota-anti-mmr-vhh2 is also rated in:

carotid stenosisDormant
C
Indicative ·
36 / 100
View asset →
atherosclerosisDormant
C
Indicative ·
36 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →